How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Breakthrough in Female Fertility Research Points, Paving the Way for New Treatments

Scientists have made a significant discovery in the field of female fertility, offering hope for millions of women struggling with infertility worldwide. In a groundbreaking study conducted by researchers from the FinnGen project, scientists have uncovered genetic mutations that could explain a significant portion of previously unexplained female infertility. The findings, published in The American Journal of Human Genetics, highlight rare mutations in the TBPL2 gene as a major factor impairing reproductive ability, with potential implications for personalized fertility treatments.

Fig. Potential therapeutic targets for female infertility.

Key discovery: A rare mutation in TBPL2 is linked to infertility

The genome-wide association study (GWAS) on 22,849 infertile women and 198,989 controls identified key genetic contributors to infertility. Recessive models found two loci: polycystic kidney and hepatic disease-like 1 (PKHD1L1), previously linked to infertility, and novel TATA-box binding protein-like 2 (TBPL2). The TBPL2 locus on chromosome 14 showed the strongest recessive association, with a rare mutation (p.Arg299Ter; rs144313315) enriched in Finland. Homozygous carriers had fewer offspring with all births requiring infertility treatment. This mutation’s severe impact, absent in PKHD1L1, aligns with mouse studies linking TBPL2 loss to anovulation.

Additive models identified four loci near Wnt Family Member 4 (WNT4), sulfotransferase Family 1B Member 1 (SULT1B1), estrogen Receptor 1 (ESR1), and PKHD1L1, with fine-mapping adding another association in ESR1. While PKHD1L1 and TBPL2 acted recessively, other loci showed additive effects and pleiotropy, linking them to disorders like endometriosis, polycystic ovarian syndrome (PCOS), and fibroids. Recessive loci were exclusive to infertility.

Age-Dependent Genetic Influences

Female fertility declines more rapidly after the early 30s, prompting age-stratified analyses to explore genetic susceptibility.

Early-Onset Infertility (diagnosed before 30): Two loci, near CHEK2 and the MHC region including a frameshift mutation in CHEK2 (c.1100delC), were associated with infertility diagnosed before age 30. CHEK2, a tumor suppressor gene, is also linked to polycystic ovary syndrome (PCOS) and increased breast cancer risk. Its role in ovarian reserve and reproductive aging necessitates further exploration. CHEK2 mutations delay menopause and slow ovarian reserve depletion in mice, although their direct role in infertility remains unclear. A locus in the MHC region suggests immune tolerance mechanisms involving natural killer (NK) cells may influence infertility.

Late-Onset Infertility (diagnosed after 30): A locus in a long non-coding RNA (lncRNA) gene was exclusively associated with infertility diagnosed after age 30, hinting at novel regulatory mechanisms in reproductive aging.

Pleiotropy with Other Reproductive Disorders

The GWAS analyses revealed pleiotropic associations between infertility and female reproductive disorders such as PCOS, endometriosis, and uterine leiomyoma. Infertility showed the strongest genetic correlation with endometriosis, consistent across early- and late-onset cases. While PCOS was significantly enriched among women with infertility, the genetic correlation was weaker but notably stronger in early-onset cases. These findings highlight varying degrees of genetic overlap between infertility and related reproductive conditions. Heritability estimates further support these relationships.

Study Limitations

• Misclassification Risk: Approximately 20% of infertility cases were based solely on medication records, potentially including male-factor infertility cases.

• Age Cutoff: Using 30 years as the cutoff for late-onset infertility, rather than 35, may have reduced statistical power due to fewer cases meeting stricter criteria.

Despite these limitations, the study highlights the significant role of low-frequency recessive variants, particularly TBPL2, in female infertility, offering new insights into its genetic underpinnings.

A window into global impact

While the findings focus on the Finnish population, they offer a framework for exploring genetic infertility in diverse populations worldwide. The enrichment of rare mutations due to Finland’s unique genetic history highlights the potential for uncovering similar variants in other groups.

The bigger picture

With infertility affecting nearly 20% of women globally, this research brings renewed hope for those struggling to conceive. As scientists continue to unravel the genetic complexities of reproduction, the future of personalized fertility treatments seems closer than ever.

Hope for new treatments

The findings from the current study open the door to transformative advancements in fertility care, highlighting several potential targeted approaches to consider:

Gene replacement therapy for TBPL2 mutations for restoration of normal TBPL2 function, enabling proper oocyte development and maturation
• CRISPR-Cas9 editing: Correct the stop codon mutation in TBPL2 in oocytes or ovarian cells using precise base editing or homology-directed repair.
• Gene delivery: Introduce a functional TBPL2 gene copy into ovarian cells using a viral vector (e.g., AAV or lentivirus) to compensate for the loss-of-function (LoF) mutation.

CHEK2 mutation targeting for improved ovarian function and reduced PCOS-related infertility
• RNAi or CRISPR interference: Suppress the dominant-negative or deleterious CHEK2 variant allele to reduce its influence on fertility pathways.
• Gene augmentation: Provide a functional CHEK2 allele to restore normal checkpoint functions without inducing tumorigenic risks.

Immune modulation for MHC region variants for enhanced embryo implantation and maintenance of pregnancy
• Cytokine therapy: Modulate immune responses to improve local immune tolerance in the uterus.
• Gene therapy: Target and correct specific non-classical MHC class I variants using CRISPR-based approaches or RNA-guided therapies.

Oocyte-specific gene editing for the production of viable oocytes capable of successful fertilization and embryo development.
• Zygote or germline editing: Use CRISPR-based gene editing to repair mutations before fertilization or during early embryonic development.
• Ex vivo oocyte gene editing: Retrieve oocytes, perform gene editing in vitro, and use them for IVF procedures.

Targeted therapies for PCOS-associated infertility for improved ovulation and pregnancy rates
• Gene silencing: Inhibit pathways hyperactivated by PCOS-associated variants using siRNA or antisense oligonucleotides.
• Metabolic modulation: Enhance insulin sensitivity and hormonal balance via targeted gene therapy.
• Expected Outcome.

Age-dependent therapy development for the reduction of infertility rates across age groups
• Custom therapeutics: Design therapies targeting loci uniquely associated with early- or late-onset infertility.
• Combined gene and hormonal therapy: Integrate gene therapy with hormonal treatments tailored to the patient’s age and genetic profile.